Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty

Canadian Journal of Cardiology

Volumn 15, Issue 2, 1999, Pages 201-207

  McGregor, Maurice ^a,c   Brophy, James M ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Angioplasty; Balloon; Glycoproteins; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT;

ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVASCULARIZATION;

ANGIOPLASTY, BALLOON; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CORONARY DISEASE; COSTS AND COST ANALYSIS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033035571     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
2. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
3. Chronos N, Vahanian A, Betriu A, et al. Use of abciximab in interventional cardiology. Am Heart J 1998;135:S67-76.
4. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
5. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
6. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary-intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;343:881-6.
7. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734-41.
8. Zed PJ, Frighetto L, Sunderji R, Marra CA. Cost-effectiveness analysis of abciximab: a Canadian hospital perspective. Ann Pharmacother 1998;32:536-42.
9. Ferguson JJ, Kereiakes DJ, Adgey AA, et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J 1998;135:S77-89.
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
11. Thisted RA. Elements of Statistical Computing. New York: Chapman and Hall, 1998.
12. Adelman AG, Caramori PR, Cohen EA, et al. The role of glycoprotein IIb/IIIa platelet inhibition in percutaneous coronary intervention in the stent era. Can J Cardiol 1998;14:1057-66.
13. Aristides M, Gliksman M, Rajan N, Davey P. Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients. Heart 1998;79:12-7.
14. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996;94:629-35.
15. van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. Eur Heart J 1995;16(Suppl L):81-5.
16. Goktaney AK, Murphy JD, Hillegass WB Jr. Abciximab therapy in percutaneous intervention: economic issues in the United States. Am Heart J 1998;135:590-7.
17. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997;278:479-84.
18. Cardiac Care Network of Ontario. Expert Review Panel on Intracoronary Stents and Abciximab. Willowdale: Cardiac Care Network of Ontario, 1998
19. Higginson LAJ, Naylor CD. Rates of cardiac catheterization, coronary angioplasty and coronary artery bypass surgery in Canada. Can J Cardiol 1997;13(Suppl D):47D-52D.
20. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
21. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994:331:496-501.
22. Hamm CW, Heeschen C, Goldman B, et al. Troponin T predicts the benefit of abciximab in patients with unstable angina in the CAPTURE study. 20th Congress of the European Society of Cardiology. Vienna, August 22-26, 1998. [Abst 766]
23. Heeschen C, Hamm CW, Goldman BU, et al. Cost effectiveness of treatment with abciximab in patients with unstable angina according to troponin status - Results from the CAPTURE trial. 20th Congress of the European Society of Cardiology. Vienna, August 22-26, 1998. (Abst P2212)